Skip to main content
Premium Trial:

Request an Annual Quote

Knome Lands Two Customers for Whole-Genome Sequencing

NEW YORK (GenomeWeb News) — The personal whole genome startup company Knome said today it has lined up the first two customers for its DNA sequencing and analysis service, which it offers through a partnership with the Beijing Genomics Institute.
Knome said the two individuals would be the first in the world to have their genomes sequenced by a personal genomics firm.
J. Craig Venter and James Watson were the first humans to have their genomes sequenced as part of sponsored research efforts, Knome noted, and recently BGI said it performed a full sequencing on a Chinese scientist who will remain anonymous.
Knome VP of Sales and Business Development Ari Kiirikki said the two individuals have chosen to remain anonymous as well, adding that the company’s service includes “a variety of processes and tools to keep their genomic identity private and secure.”
Cambridge, Mass.-based Knome is marketing its whole-genome sequencing and genomic analysis, which costs around $350,000, to an initial group of about 20 customers worldwide.
“Whole-genome sequencing represents the future of personalized medicine and these sequenced genomes will nearly double the amount of whole-genome information available today,” said George Church, a founder of the company and a genetics professor at Harvard Medical School.
Zhuo Li, BGI’s VP of international collaboration, said the firm expects to complete the sequencing for the two clients sometime “in the coming months.”
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.